Skip to main content

Table 1 Frequency of chromosomal abnormalities in mouse bone marrow induced after treatment with CP and MEAC

From: Albizia chinensis bark extract ameliorates the genotoxic effect of cyclophosphamide

Treatments and doses (mg/kg) Total abnormal metaphases No. of different types of abnormal metaphases Inhibitory index excluding gaps
No. Mean(%) ± SE G. Frag. and/or Br. Del. C.F. M.A. Polyp.
Including gaps Excluding gaps
I. Control 23 4.60 ± 0.58 2.60 ± 0.48a 10 9 4 0 0 0
II.CP (20) 119 23.80 ± 0.52a 19.20 ± 0.60d 23 43 10 6 32 5
III. MEAC (100) 23 4.60 ± 0.50 2.40 ± 0.62a 11 8 4 0 0 0
IV. MEAC (25 × 7 days) 25 5.00 ± 0.58 3.00 ± 0.52a 10 12 3 0 0 0
Single dose
 V. MEAC (25) + CP 113 22.60 ± 0.54a 18.20 ± 0.50d 22 52 9 4 21 5 7
 VI. MEAC (50) + CP 107 21.40 ± 0.70a 16.80 ± 0.65d 23 50 6 3 23 2 15
 VII. MEAC(100) + CP 91 18.20 ± 0.65ab 14.00 ± 0.55bc 21 45 7 1 15 2 32
Repeated dose
 VIII. MEAC (25 × 3 days) + CP 105 21.00 ± 0.58a 16.60 ± 0.70d 22 49 9 2 20 3 16
 IX. MEAC (25 × 7 days) + CP 85 17.00 ± 0.56ab 13.00 ± 0.65bc 20 42 5 1 16 1 38
  1. Total number of examined metaphases 500 (100 metaphases/animal, 5 animals/group)
  2. The values having different superscript letters in each column are significantly different from one another as calculated by ANOVA
  3. G. gap, Frag. fragment, Br. breaks, Del. deletions, C.F. centric fusions, M.A. multiple aberrations, Polyp polyploidy